SGLT2 Inhibitors
4 articles on SGLT2 Inhibitors, written by Shotlee and medically reviewed for clinical accuracy.
GLP-1s Don't Work for Everyone: What to Know If Not Seeing Results
Started GLP-1s for weight loss or blood sugar control but seeing no results? New research in Genome Medicine reveals that 10% of people carry PAM gene variants linked to weaker responses. Experts explain genetics, common pitfalls, testing, and effective alternatives to help you succeed.
7 min read
GLP-1 and SGLT2 Combo Cuts Mortality 29% in T2D Study
A large German study reveals that pairing GLP-1 receptor agonists with SGLT2 inhibitors significantly lowers all-cause mortality and cardiovascular risks in type 2 diabetes patients compared to SGLT2 inhibitors alone. Common combinations like dulaglutide plus empagliflozin showed a 29% mortality reduction. Experts highlight synergy but urge caution on potential harms.
5 min read
How Drugs Like Ozempic Revolutionize Kidney Treatment
Chronic kidney disease affects over one in seven Americans, but new drugs like Ozempic are changing the game. GLP-1 receptor agonists, SGLT2 inhibitors, and finerenone offer additive benefits beyond traditional RAS inhibitors, potentially halting or reversing progression. Experts like Maarten Taal hail them as game-changers for kidney health.
5 min read
Study: Ozempic, Wegovy NAION Risk Twofold Higher vs. SGLT2i Drugs
New research from Veterans' Affairs shows Ozempic and Wegovy users face double the risk of NAION—a serious vision loss condition—compared to SGLT2i drugs. Published in JAMA Ophthalmology, the study urges doctors to warn patients about potential permanent blindness from semaglutide-based GLP-1 medications. As lawsuits mount, understand the implications for diabetes and weight management.
5 min read